바카라 디시

Christoph Hamann, the Managing Director of Merck Biopharma 바카라 디시, has set the company’s goals for 2025 as achieving reimbursement for key oncology products and improving South 바카라 디시n access to innovative drugs. Since his appointment as head of Merck Biopharma 바카라 디시 in November 2022, Hamann has built his career through strategic and commercial roles in major markets such as Germany, Switzerland, and the United States, excelling in business development (BD) and management.

In an interview with the global pharmaceutical press group in 2023, marking his first anniversary in the role, Hamann declared his ambition to position the 바카라 디시n market as the top performer in the APAC region. His vision extended beyond financial success to business expansion and contributing to addressing 바카라 디시’s low birthrate challenges. For his second anniversary in 2024, Hamann shared insights into the progress achieved so far and the company’s objectives for the year ahead.

Last year, Merck 바카라 디시 BioPharma aimed to strengthen its Specialty Care pipeline and establish 바카라 디시 as the top APAC market. How has this goal progressed this year?

“We’ve achieved several notable successes. Most importantly, we’ve expanded access to 바카라 디시’s Specialty Care portfolio.

In the infertility sector, since April, access to Pergoveris has improved, allowing patients with LH (luteinizing hormone) and FSH (follicle-stimulating hormone) deficiencies easier access to treatment. Women aged 35 and above, who form the majority of 바카라 디시’s infertility patients, frequently face LH or FSH deficiencies. This expanded accessibility to Pergoveris is expected to help many patients in their journey toward parenthood.

In oncology, in April 2023, we renewed the third RSA agreement for Erbitux, extending treatment benefits for patients. This year, the combination therapy of Erbitux and Braftovi (encorafenib) demonstrated efficacy in patients with metastatic colorectal cancer harboring the BRAF V600E mutation, leading to expanded reimbursement.

Meanwhile, Tepmetko, a treatment for MET exon 14 skipping lung cancer, achieved a critical milestone by passing the Cancer Disease Deliberation Committee after three attempts, just three years after its launch. Although challenges remain in securing reimbursement, this achievement is significant given the low five-year survival rate (9%) for patients with MET exon 14 skipping mutations. We hope reimbursement will be finalized next year to provide greater treatment opportunities. Lastly, Bavencio, a bladder cancer treatment, has shown strong performance since receiving reimbursement approval in August 2023.”

Have you achieved your goal of becoming a global leader in Specialty Care?

“We’ve successfully established 바카라 디시 as the top APAC market and are now adjusting our portfolio to target global leadership in Specialty Care.

바카라 디시 aims to be a leader in fields with high unmet medical needs, such as infertility and bladder cancer. Our focus is on providing treatments that genuinely help patients and improve their lives.”

바카라 디시 is synonymous with infertility treatment. Can you elaborate on your efforts in this field over the past year?

“Infertility is a core area for Merck. We believe all companies in 바카라 디시 should address the low birthrate issue beyond just business interests. Merck is committed to this cause, leveraging its infertility treatment portfolio to provide solutions.

For example, the expanded reimbursement of Pergoveris marks a significant step toward increasing treatment 바카라 디시. Additionally, we are working to raise awareness of infertility through scientific approaches and fostering a family-friendly workplace culture. We aim to set an example by showing that business success and family support can coexist.

Through the APAC ‘Fertility Counts’ initiative, we are also addressing low birthrates by increasing awareness and encouraging stakeholders to collaborate on this pressing issue from policy and cultural perspectives.”

Tepmetko recently passed the Cancer Disease Deliberation Committee after three years. What are your thoughts on the committee’s clinical evaluation standards?

“Tepmetko is registered in 30 countries and reimbursed in key A8 nations, including the U.S., Japan, Germany, Italy, Switzerland, and the U.K.

바카라 디시 places high importance on drug safety and efficacy, and the government’s efforts to ensure the quality and safety of imported medicines are commendable. However, limited budgets pose challenges to achieving the goal of universal healthcare.

We hope for a balanced approach where the government, healthcare providers, and the pharmaceutical industry work together to provide safe and effective medicines while optimizing budget allocation. Improved accessibility would enable 바카라 디시n patients to benefit from essential treatments.”

Some pharmaceutical companies withdraw products after reimbursement approvals. How does 바카라 디시 handle coordination with headquarters on reimbursement, and what efforts are made to secure reimbursement?

“When withdrawing products, business decline often plays a role. However, Merck has never withdrawn a product in 바카라 디시. We remain dedicated to growing our presence and helping patients. This involves close collaboration with the government to ensure continued patient access to our therapies.”

How is Merck engaging in open innovation with 바카라 디시n companies?

“바카라 디시’s rapidly growing biotech sector is attracting attention from Merck and other global pharmaceutical companies.

Recently, many of our global business development teams have visited 바카라 디시 to explore collaboration opportunities with biotech companies. Several licensing agreements have been signed over the years, and we hope the ecosystem will continue to evolve, creating more opportunities. For 바카라 디시 to achieve its goal of becoming a biotech innovation hub, systematic advancements in evaluating and recognizing innovation are also necessary.”

As you enter your third year as GM, what are your personal goals and Merck 바카라 디시 BioPharma’s vision for next year?

“There are three main goals. First, we aim to secure reimbursement for all remaining products in 2025.

Second, we aspire to establish 바카라 디시 as a role model and leader in addressing the low birthrate issue, creating a family-friendly workplace culture.

Third, as a member of the 바카라 디시 Research-based Pharmaceutical Industry Association (KRPIA), we are committed to improving access to new drugs in 바카라 디시. The process of securing reimbursement for new drugs takes a long time, and the number of new drugs introduced is relatively low. We will work closely with the government to find the best balance so that 바카라 디시n patients can enjoy greater benefits from new treatments.”